Clinical trials support us
RESEARCH AND DEVELOPMENT
THE CUTTING EDGE OF BIOTECHNOLOGICAL INNOVATION IN MEDICINAL MUSHROOMS
At Hifas da Terra we are committed to innovation and scientific research, offering solutions that improve people’s health and wellbeing through pre-clinical and clinical trials in which the efficacy of our products is tested and proven.
In this way we cross the biotech frontier and make our way into biopharma, researching new patentable products as well as new medical devices status for areas not currently covered by pharmacology. Our target is to contribute to a healthier and more protected society.
KEY R&D&I DATA
WE ALLOCATE 62% OF OUR PROFITS TO R&D
MORE THAN 200 MULTI-DISCIPLINARY EXPERTS WORK WITH US
We have our own large scientific team and more than 200 multidisciplinary collaborators. Some of the entities with which we collaborate include:
- Galicia South Biomedical Foundation
- Foltra Foundation
- Ourense University Hospital
- Meixoeiro Hospital
MORE THAN 15 ACTIVE PROJECTS
We are the leading biotech in natural product research and development, with more than 15 active studies including controlled clinical trials in oncology patients, as well as quality clinical research in the area of women’s health, gut microbiota and in patients with COVID-19 and long COVID, SIBO-Irritable Bowel Syndrome, DAO deficiency and diverticular disease.
SCIENTIFIC AND BIOTECHNOLOGICAL INNOVATION
Through innovation we elaborate new processes and protocols that have a positive impact on people’s well-being. We do this by building on existing evidence from medicinal mushrooms and clinical research and introducing innovative and sustainable technological processes and smart 4.0 technologies. The result is the creation of a new model of safe and effective food supplements that answer real needs.
IWe innovate in the organic cultivation of medicinal mushrooms by introducing sustainable production in bioreactors, a pioneering system that allows us to cultivate mycelium under standardised conditions and expands the medical applications of the extracts by varying culture media, selecting specific strains oriented to results, etc. This system also allows us to more efficiently isolate active biomolecules and new ingredients that improve our nutritional supplements.
We are laying the foundations for what we call “mycotherapy à la carte”, i.e. the formulation of novel products to address specific situations and specific genetic conditions. Currently, at Hyfas da Terra we already conduct studies to demonstrate the safety and efficacy of our products, a global standard of excellence that applies to all new projects and products.
The know-how acquired thanks to the scientific and technological expertise of our R&D&I team opens the door to the creation of new patents based on medicinal mushrooms and their applications, whether it be in the form of food supplements or medical devices, amongst others.
Conducting model studies and clinical trials in patients with prevalent diseases and symptoms.
THERAPEUTIC AREAS OF RESEARCH
CLINICAL TRIALS 2020 – 2025
Micromarker
2018 – 2023
- 2021
- Randomised double-blind vs. placebo clinical trial in colorectal cancer (Mico-Digest 2.0)
- Patients: 144
- Medical centre: Fundación Biomédica Galicia Sur / Complejo Hospitalario Público de Ourense
Microinmunomama
2020 – 2023
- Planned start 2021
- Randomised, double-blind, placebo-controlled clinical trial in breast cancer (Mico-Mama 2.0)
- Patients: > 100, exact number to be determined
- Medical centre: Fundación Biomédica Galicia Sur / Complejo Hospitalario Público Álvaro Cunqueiro in Vigo
Other R&D projects and observational studies in humans
Nutrigen 4.0
2021 – 2024
- Implementation of Intelligent Processes for the production of nutritional supplements based on the analysis of new biosynthetic pathways in the genomes of two strains of edible mushrooms from Galicia.
Covid-19 study in residences
2020
- Observational study in patients with SARS-COV-2 tested with PCR and/or laboratory tests compatible with active COVID-19 infection under supplementation with HdT fungal extracts.
- Patients: 76
- Medical centre: Centro De Asistencia Médico Geriátrico Leganés / Dr. Soler
Mico-Artro
2018
- Effects of two mushroom extracts on symptom relief in patients with osteoarthritis: Observations in daily clinical practice.
- Patients: 20
- Medical centre: OAFI (International Osteoarthritis Foundation) / Dr. S. Moller
Neurofood
2018 – 2021
- R&D project with human trial on the effects of medicinal mushrooms from Hifas da Terra on memory and cognition in healthy adults. Possible implications in cognitive decline or neurodegenerative pathologies (Alzheimer’s, Parkinson’s).
- Patients: 40
- Medical centre: Centro Sanitario Foltra / Dr. Devesa
FungitechOnco
2019 – 2021
- Industrial development of the cultivation of medicinal mushroom species to attain new compounds with anticarcinogenic activity applicable in products aimed at the prevention and treatment of gastric and colorectal cancers.
Dismetasín
2018 – 2021
- Ingredients with health properties in the industrial development of target foods to reduce the incidence of metabolic syndrome. Clinical trial on the effects of Mico-MIX in patients with metabolic syndrome.
- Patients: 68
- Medical centre: Complejo Hospitalario de Santiago de Compostela / Dr Felipe Casanueva
SCIENTIFIC PUBLICATIONS
Previous
Next